{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T02:03:20Z","timestamp":1784685800003,"version":"3.55.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":57,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-026-04416-w","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T13:55:21Z","timestamp":1779803721000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["IAR025, a novel anti-DLL3 x CD3-bispecific antibody, displays high antitumor efficacy in preclinical models of small-cell lung cancer"],"prefix":"10.1007","volume":"75","author":[{"given":"Yang","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengqiu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ninghuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengjia","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihui","family":"Kuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijun","family":"Sha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinling","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihai","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"key":"4416_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41572-020-00235-0","volume":"7","author":"CM Rudin","year":"2021","unstructured":"Rudin CM, Brambilla E, Faivre-Finn C, Sage J (2021) Small-cell lung cancer. Nat Rev Dis Primers 7:3. https:\/\/doi.org\/10.1038\/s41572-020-00235-0","journal-title":"Nat Rev Dis Primers"},{"key":"4416_CR2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jtho.2022.10.002","volume":"18","author":"Q Wang","year":"2023","unstructured":"Wang Q, G\u00fcm\u00fc\u015f ZH, Colarossi C et al (2023) SCLC: epidemiology, risk factors, genetic susceptibility, molecular pathology, screening, and early detection. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer 18:31\u201346. https:\/\/doi.org\/10.1016\/j.jtho.2022.10.002","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer"},{"key":"4416_CR3","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000029783","volume":"101","author":"M Stokes","year":"2022","unstructured":"Stokes M, Berfeld N, Gayle A et al (2022) A systematic literature review of real-world treatment outcomes of small cell lung cancer. Medicine (Baltimore) 101:e29783. https:\/\/doi.org\/10.1097\/MD.0000000000029783","journal-title":"Medicine (Baltimore)"},{"key":"4416_CR4","doi-asserted-by":"publisher","first-page":"e35710","DOI":"10.7759\/cureus.35710","volume":"15","author":"A \u0130lhan","year":"2023","unstructured":"\u0130lhan A, Gurler F, Yilmaz F et al (2023) Clinicopathological features and first-line treatment outcomes of geriatric patients with extensive-stage small cell lung cancer: a multicenter study. Cureus 15:e35710. https:\/\/doi.org\/10.7759\/cureus.35710","journal-title":"Cureus"},{"key":"4416_CR5","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s12890-025-03625-w","volume":"25","author":"M Erciyestepe","year":"2025","unstructured":"Erciyestepe M, Ekinci \u00d6B, Do\u011fan HGY et al (2025) Factors affecting survival and prognosis in extensive stage small cell lung cancer. BMC Pulm Med 25:160. https:\/\/doi.org\/10.1186\/s12890-025-03625-w","journal-title":"BMC Pulm Med"},{"key":"4416_CR6","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","volume":"379","author":"L Horn","year":"2018","unstructured":"Horn L, Mansfield AS, Szcz\u0229sna A et al (2018) First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med 379:2220\u20132229. https:\/\/doi.org\/10.1056\/NEJMoa1809064","journal-title":"N Engl J Med"},{"key":"4416_CR7","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S1470-2045(20)30539-8","volume":"22","author":"JW Goldman","year":"2021","unstructured":"Goldman JW, Dvorkin M, Chen Y et al (2021) Durvalumab, with or without tremelimumab, plus platinum\u2013etoposide versus platinum\u2013etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 22:51\u201365. https:\/\/doi.org\/10.1016\/S1470-2045(20)30539-8","journal-title":"Lancet Oncol"},{"key":"4416_CR8","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1200\/JCO.1999.17.2.658","volume":"17","author":"J Von Pawel","year":"1999","unstructured":"Von Pawel J, Schiller JH, Shepherd FA et al (1999) Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 17:658\u2013658. https:\/\/doi.org\/10.1200\/JCO.1999.17.2.658","journal-title":"J Clin Oncol"},{"key":"4416_CR9","doi-asserted-by":"publisher","first-page":"5441","DOI":"10.1200\/JCO.2006.06.5821","volume":"24","author":"MER O\u2019Brien","year":"2006","unstructured":"O\u2019Brien MER, Ciuleanu T-E, Tsekov H et al (2006) Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol 24:5441\u20135447. https:\/\/doi.org\/10.1200\/JCO.2006.06.5821","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"4416_CR10","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/S1470-2045(20)30068-1","volume":"21","author":"J Trigo","year":"2020","unstructured":"Trigo J, Subbiah V, Besse B et al (2020) Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. Lancet Oncol 21:645\u2013654. https:\/\/doi.org\/10.1016\/S1470-2045(20)30068-1","journal-title":"Lancet Oncol"},{"key":"4416_CR11","doi-asserted-by":"publisher","first-page":"e70289","DOI":"10.1002\/cnr2.70289","volume":"8","author":"J Bar","year":"2025","unstructured":"Bar J, Xu Q, Karve S et al (2025) Real-world response and survival outcomes and treatment patterns in patients with extensive stage small-cell lung cancer receiving third-line treatment. Cancer Rep Hoboken 8:e70289. https:\/\/doi.org\/10.1002\/cnr2.70289","journal-title":"Cancer Rep Hoboken"},{"key":"4416_CR12","doi-asserted-by":"publisher","first-page":"2984","DOI":"10.1111\/cas.15017","volume":"112","author":"K Matsuo","year":"2021","unstructured":"Matsuo K, Taniguchi K, Hamamoto H et al (2021) Delta-like canonical Notch ligand 3 as a potential therapeutic target in malignancies: a brief overview. Cancer Sci 112:2984\u20132992. https:\/\/doi.org\/10.1111\/cas.15017","journal-title":"Cancer Sci"},{"key":"4416_CR13","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1083\/jcb.200702009","volume":"178","author":"I Geffers","year":"2007","unstructured":"Geffers I, Serth K, Chapman G et al (2007) Divergent functions and distinct localization of the Notch ligands DLL1 and DLL3 in vivo. J Cell Biol 178:465\u2013476. https:\/\/doi.org\/10.1083\/jcb.200702009","journal-title":"J Cell Biol"},{"key":"4416_CR14","doi-asserted-by":"publisher","first-page":"302ra136","DOI":"10.1126\/scitranslmed.aac9459","volume":"7","author":"LR Saunders","year":"2015","unstructured":"Saunders LR, Bankovich AJ, Anderson WC et al (2015) A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. Sci Transl Med 7:302ra136. https:\/\/doi.org\/10.1126\/scitranslmed.aac9459","journal-title":"Sci Transl Med"},{"key":"4416_CR15","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/nm.4239","volume":"23","author":"L Carter","year":"2017","unstructured":"Carter L, Rothwell DG, Mesquita B et al (2017) Molecular analysis of circulating tumor cells identifies distinct copy-number profiles in patients with chemosensitive and chemorefractory small-cell lung cancer. Nat Med 23:114\u2013120. https:\/\/pubmed.ncbi.nlm.nih.gov\/27869802\/","journal-title":"Nat Med"},{"key":"4416_CR16","doi-asserted-by":"publisher","first-page":"14788","DOI":"10.1073\/pnas.1410419111","volume":"111","author":"A Augustyn","year":"2014","unstructured":"Augustyn A, Borromeo M, Wang T et al (2014) ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers. Proc Natl Acad Sci U S A 111:14788\u201314793. https:\/\/doi.org\/10.1073\/pnas.1410419111","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4416_CR17","doi-asserted-by":"publisher","first-page":"104136","DOI":"10.1016\/j.critrevonc.2023.104136","volume":"191","author":"W Yang","year":"2023","unstructured":"Yang W, Wang W, Li Z et al (2023) Delta-like ligand 3 in small cell lung cancer: potential mechanism and treatment progress. Crit Rev Oncol Hematol 191:104136. https:\/\/doi.org\/10.1016\/j.critrevonc.2023.104136","journal-title":"Crit Rev Oncol Hematol"},{"key":"4416_CR18","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1158\/1078-0432.CCR-20-2845","volume":"27","author":"MJ Giffin","year":"2021","unstructured":"Giffin MJ, Cooke K, Lobenhofer EK et al (2021) AMG 757, a half-life extended, DLL3-targeted bispecific T-cell engager, shows high potency and sensitivity in preclinical models of small-cell lung cancer. Clin Cancer Res 27:1526\u20131537. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-2845","journal-title":"Clin Cancer Res"},{"key":"4416_CR19","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1056\/NEJMoa2307980","volume":"389","author":"M-J Ahn","year":"2023","unstructured":"Ahn M-J, Cho BC, Felip E et al (2023) Tarlatamab for patients with previously treated small-cell lung cancer. N Engl J Med 389:2063\u20132075. https:\/\/doi.org\/10.1056\/NEJMoa2307980","journal-title":"N Engl J Med"},{"key":"4416_CR20","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1056\/NEJMoa2502099","volume":"393","author":"G Mountzios","year":"2025","unstructured":"Mountzios G, Sun L, Cho BC et al (2025) Tarlatamab in small-cell lung cancer after platinum-based chemotherapy. N Engl J Med 393:349\u2013361. https:\/\/doi.org\/10.1056\/NEJMoa2502099","journal-title":"N Engl J Med"},{"key":"4416_CR21","doi-asserted-by":"publisher","first-page":"8090","DOI":"10.1200\/JCO.2024.42.16_suppl.8090","volume":"42","author":"H Beltran","year":"2024","unstructured":"Beltran H, Johnson ML, Jain P et al (2024) Updated results from a phase 1\/2 study of HPN328, a tri-specific, half-life (T1\/2) extended DLL3-targeting T-cell engager in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine cancers (NEC). J Clin Oncol 42:8090\u20138090. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.8090","journal-title":"J Clin Oncol"},{"key":"4416_CR22","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1200\/JCO-25-00363","volume":"43","author":"M Wermke","year":"2025","unstructured":"Wermke M, Gambardella V, Kuboki Y et al (2025) Phase I dose-escalation results for the Delta-Like Ligand 3\/CD3 IgG-like T-cell engager Obrixtamig (BI 764532) in patients with Delta-Like Ligand 3+ small cell lung cancer or neuroendocrine carcinomas. J Clin Oncol 43:3021\u20133031. https:\/\/doi.org\/10.1200\/JCO-25-00363","journal-title":"J Clin Oncol"},{"key":"4416_CR23","doi-asserted-by":"publisher","first-page":"e0260954","DOI":"10.1371\/journal.pone.0260954","volume":"16","author":"I Wilkinson","year":"2021","unstructured":"Wilkinson I, Anderson S, Fry J et al (2021) Fc-engineered antibodies with immune effector functions completely abolished. PLoS ONE 16:e0260954. https:\/\/doi.org\/10.1371\/journal.pone.0260954","journal-title":"PLoS ONE"},{"key":"4416_CR24","doi-asserted-by":"publisher","first-page":"1871171","DOI":"10.1080\/19420862.2020.1871171","volume":"13","author":"W Chen","year":"2021","unstructured":"Chen W, Yang F, Wang C et al (2021) One size does not fit all: navigating the multi-dimensional space to optimize T-cell engaging protein therapeutics. MAbs 13:1871171. https:\/\/doi.org\/10.1080\/19420862.2020.1871171","journal-title":"MAbs"},{"key":"4416_CR25","doi-asserted-by":"publisher","first-page":"5258","DOI":"10.1158\/1078-0432.CCR-20-0926","volume":"26","author":"S Hipp","year":"2020","unstructured":"Hipp S, Voynov V, Drobits-Handl B et al (2020) A bispecific DLL3\/CD3 IgG-like T-cell engaging antibody induces antitumor responses in small cell lung cancer. Clin Cancer Res 26:5258\u20135268. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-0926","journal-title":"Clin Cancer Res"},{"key":"4416_CR26","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41698-024-00739-y","volume":"8","author":"AG Serrano","year":"2024","unstructured":"Serrano AG, Rocha P, Freitas Lima C et al (2024) Delta-like ligand 3 (DLL3) landscape in pulmonary and extra-pulmonary neuroendocrine neoplasms. npj Precis Oncol 8:268. https:\/\/doi.org\/10.1038\/s41698-024-00739-y","journal-title":"npj Precis Oncol"},{"key":"4416_CR27","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1002\/(sici)1097-0320(19970101)27:1<71::aid-cyto9>3.0.co;2-o","volume":"27","author":"A Caruso","year":"1997","unstructured":"Caruso A, Licenziati S, Corulli M et al (1997) Flow cytometric analysis of activation markers on stimulated T cells and their correlation with cell proliferation. Cytometry 27:71\u201376. https:\/\/doi.org\/10.1002\/(sici)1097-0320(19970101)27:1%3c71::aid-cyto9%3e3.0.co;2-o","journal-title":"Cytometry"},{"key":"4416_CR28","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/sj.bjc.6603810","volume":"97","author":"H Okamoto","year":"2007","unstructured":"Okamoto H, Watanabe K, Kunikane H et al (2007) Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702. Br J Cancer 97:162\u2013169. https:\/\/doi.org\/10.1038\/sj.bjc.6603810","journal-title":"Br J Cancer"},{"key":"4416_CR29","doi-asserted-by":"publisher","first-page":"100889","DOI":"10.1016\/j.tranon.2020.100889","volume":"14","author":"W Huang","year":"2021","unstructured":"Huang W, Chen J-J, Xing R, Zeng Y-C (2021) Combination therapy: future directions of immunotherapy in small cell lung cancer. Transl Oncol 14:100889. https:\/\/doi.org\/10.1016\/j.tranon.2020.100889","journal-title":"Transl Oncol"},{"key":"4416_CR30","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.jtho.2019.12.109","volume":"15","author":"HC Chung","year":"2020","unstructured":"Chung HC, Piha-Paul SA, Lopez-Martin J et al (2020) Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic SCLC: results from the KEYNOTE-028 and KEYNOTE-158 studies. J Thorac Oncol 15:618\u2013627. https:\/\/doi.org\/10.1016\/j.jtho.2019.12.109","journal-title":"J Thorac Oncol"},{"key":"4416_CR31","unstructured":"Wermke M DAREONTM-9, a phase Ib study of obrixtamig plus topotecan in patients (pts) with advanced small cell lung cancer (SCLC): Interim analysis results. J Clin Oncol. https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2025.43.16_suppl.8094"},{"key":"4416_CR32","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee DW, Gardner R, Porter DL et al (2014) Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124:188\u2013195. https:\/\/doi.org\/10.1182\/blood-2014-05-552729","journal-title":"Blood"},{"key":"4416_CR33","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","volume":"127","author":"JN Brudno","year":"2016","unstructured":"Brudno JN, Kochenderfer JN (2016) Toxicities of chimeric antigen receptor T cells: recognition and management. Blood 127:3321\u20133330. https:\/\/doi.org\/10.1182\/blood-2016-04-703751","journal-title":"Blood"},{"key":"4416_CR34","doi-asserted-by":"publisher","first-page":"TPS8126\u2013TPS8126","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS8126","volume":"42","author":"TK Owonikoko","year":"2024","unstructured":"Owonikoko TK, Byers LA, Cheng Y et al (2024) IDeate-Lung02: a phase 3, randomized, open-label study of ifinatamab deruxtecan (I-DXd) vs treatment of physician\u2019s choice (TPC) in relapsed small cell lung cancer (SCLC). J Clin Oncol 42:TPS8126\u2013TPS8126. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.TPS8126","journal-title":"J Clin Oncol"},{"key":"4416_CR35","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1016\/j.jtho.2025.09.046","volume":"20","author":"Y Cheng","year":"2025","unstructured":"Cheng Y, Meng X, Zhang Y et al (2025) OA06.01 a first-in-human phase 1 study of SHR-4849 (IDE849), a DLL3-directed antibody-drug conjugate, in relapsed SCLC. J Thorac Oncol 20:S21. https:\/\/doi.org\/10.1016\/j.jtho.2025.09.046","journal-title":"J Thorac Oncol"},{"key":"4416_CR36","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1200\/JCO.2025.43.16_suppl.3041","volume":"43","author":"MR Patel","year":"2025","unstructured":"Patel MR, Wu Y-LLC, Wang Z et al (2025) ZL-1310, a DLL3 ADC, in patients with extensive stage small cell lung cancer: Ph1 trial update. J Clin Oncol 43:3041. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.3041","journal-title":"J Clin Oncol"},{"key":"4416_CR37","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1016\/j.jtho.2025.09.049","volume":"20","author":"LA Byers","year":"2025","unstructured":"Byers LA, Chul Cho B, Cooper A et al (2025) OA06.04 safety and efficacy of ABBV-706, a seizure-related homolog protein 6-targeting antibody-drug conjugate, in R\/R SCLC. J Thorac Oncol 20:S23. https:\/\/doi.org\/10.1016\/j.jtho.2025.09.049","journal-title":"J Thorac Oncol"},{"key":"4416_CR38","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.jtho.2024.12.028","volume":"20","author":"A Dowlati","year":"2025","unstructured":"Dowlati A, Chiang AC, Cervantes A et al (2025) Phase 2 open-label study of Sacituzumab Govitecan as second-line therapy in patients with extensive-stage SCLC: results from TROPiCS-03. J Thorac Oncol 20:799\u2013808. https:\/\/doi.org\/10.1016\/j.jtho.2024.12.028","journal-title":"J Thorac Oncol"},{"key":"4416_CR39","doi-asserted-by":"publisher","first-page":"S577","DOI":"10.1016\/j.jtho.2025.09.1088","volume":"20","author":"M Johnson","year":"2025","unstructured":"Johnson M, Bar J, Benitez Montanez JC et al (2025) P3.18.73 a phase 1b\/2 study of Gocatamig and Ifinatamab Deruxtecan for relapsed or refractory extensive-stage small cell lung cancer. J Thorac Oncol 20:S577. https:\/\/doi.org\/10.1016\/j.jtho.2025.09.1088","journal-title":"J Thorac Oncol"},{"key":"4416_CR40","doi-asserted-by":"publisher","first-page":"76902","DOI":"10.18632\/oncotarget.12357","volume":"7","author":"J Feucht","year":"2016","unstructured":"Feucht J, Kayser S, Gorodezki D et al (2016) T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80\/CD86 on leukemic blasts. Oncotarget 7:76902\u201376919. https:\/\/doi.org\/10.18632\/oncotarget.12357","journal-title":"Oncotarget"},{"key":"4416_CR41","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jtho.2018.10.003","volume":"14","author":"N Ready","year":"2019","unstructured":"Ready N, Farago AF, de Braud F et al (2019) Third-line Nivolumab monotherapy in recurrent SCLC: CheckMate 032. J Thorac Oncol 14:237\u2013244. https:\/\/doi.org\/10.1016\/j.jtho.2018.10.003","journal-title":"J Thorac Oncol"},{"key":"4416_CR42","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1016\/S1470-2045(25)00480-2","volume":"26","author":"KG Paulson","year":"2025","unstructured":"Paulson KG, Lau SCM, Ahn M-J et al (2025) Safety and activity of Tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study. Lancet Oncol 26:1300\u20131311. https:\/\/doi.org\/10.1016\/S1470-2045(25)00480-2","journal-title":"Lancet Oncol"},{"key":"4416_CR43","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-25-1483","author":"A Mishra","year":"2026","unstructured":"Mishra A, Meador CB, Kikkeri K et al (2026) Circulating tumor cells predict response to the DLL3-targeting bispecific antibody tarlatamab. Cancer Discov. https:\/\/doi.org\/10.1158\/2159-8290.CD-25-1483","journal-title":"Cancer Discov"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-026-04416-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04416-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04416-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T01:52:16Z","timestamp":1784685136000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-026-04416-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":43,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["4416"],"URL":"https:\/\/doi.org\/10.1007\/s00262-026-04416-w","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,26]]},"assertion":[{"value":"24 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All the authors are employees of Innovent Biologics. Innovent Biologics has filed patent applications of this work.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"192"}}